IMM 124E

Drug Profile

IMM 124E

Alternative Names: Anti-LPS colostrum (Imm124-E) - Immuron; Bovine colostrum - Immuron; IMM-124E; IMM122-I

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immuron
  • Developer Emory University; Hadassah Medical Organization; Immuron; La Trobe University; University of Melbourne; University of Zurich; Virginia Commonwealth University
  • Class Antibodies; Hepatoprotectants; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alcoholic hepatitis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Preclinical Autistic disorder; Gastroenteritis
  • No development reported Metabolic syndrome

Most Recent Events

  • 21 Nov 2017 Immuron has patent protection for IMM 124E Non-alcoholic steatohepatitis in Australia before November 2017
  • 15 Nov 2017 Immuron receives patent allowance for IMM 124E for Non-alcoholic steatohepatitis in USA
  • 30 Oct 2017 Immuron completes a phase II trial in Non-alcoholic steatohepatitis in Australia, USA and Israel (PO) (NCT02316717)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top